Literature DB >> 8591853

The role of hepatobiliary scintigraphy in cystic fibrosis.

P J O'Connor1, K W Southern, I M Bowler, H C Irving, P J Robinson, J M Littlewood.   

Abstract

This was a prospective open study that examined the quantitative and qualitative analysis of hepatobiliary scintigraphy (DISIDA) in detecting liver involvement in cystic fibrosis (CF). Forty-four adult and pediatric patients (median age, 12.1 years; range, 1.1-36.3 years) were divided into three groups: group 1, no evidence of liver involvement (n = 8); group 2, biochemical evidence of liver involvement on two or more occasions (n = 26); and group 3, clinical evidence of liver disease (n = 10). In groups 1 and 2, the most common qualitative scintigraphic finding was focal intrahepatic retention of tracer (26/34 patients, 12 of whom had normal findings on ultrasonography). This finding corresponds to focal cholestasis and may warrant treatment with the choleretic agent ursodeoxycholic acid (UDCA). In the group 3 patients, the abnormal qualitative scintigraphic appearances (heterogeneous uptake of tracer and nodular liver outline) added little to the findings on ultrasonography; however, these patients had a prolonged mean hepatic clearance time compared with those in groups 1 and 2 (one-way ANOVA; P < .015). It is proposed that scintigraphy with DISIDA has a role in the detection of early liver involvement in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8591853     DOI: 10.1002/hep.510230213

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.

Authors:  Dominique Debray; Dominique Rainteau; Véronique Barbu; Myriam Rouahi; Haquima El Mourabit; Stéphanie Lerondel; Colette Rey; Lydie Humbert; Dominique Wendum; Charles-Henry Cottart; Paul Dawson; Nicolas Chignard; Chantal Housset
Journal:  Gastroenterology       Date:  2012-02-24       Impact factor: 22.682

2.  Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease.

Authors:  H A Wyatt; A Dhawan; P Cheeseman; G Mieli-Vergani; J F Price
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

Review 3.  Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.

Authors:  K Cheng; D Ashby; R Smyth
Journal:  J R Soc Med       Date:  1997       Impact factor: 18.000

Review 4.  Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Authors:  Katharine Cheng; Deborah Ashby; Rosalind L Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.